FY2025 · ended Dec 31, 2025 · Revenue $10.00M, -5.6% YoY · Filed Feb 26, 2026
Janux Therapeutics, Inc. (JANX) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $10.0 million and a net loss of $113.6 million. Free cash flow was -$83.3 million. As of Sep 30, 2026 it held $945.7 million in cash and investments and $20.4 million in total debt.
Revenue (TTM)
$23.29M
+132.9% vs year-ago TTM
Net income (TTM)
$-99.85M
+2.0% vs year-ago TTM
Operating cash flow (TTM)
$-53.58M
+23.9% vs year-ago TTM
Free cash flow (TTM)
$-54.16M
+24.1% vs year-ago TTM
EPS (TTM)
$-1.59
+5.3% vs year-ago TTM
Dividend per share
None
Shares outstanding
60.83M
+2.9% vs prior year
Net cash
$925.34M
as of Sep 30, 2026
Operating margin
-599.3%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- JANX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Diego, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1817713
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $10.0M | $10.6M | $8.1M | $8.6M | $3.6M |
| Operating income | -$157.7M | -$98.8M | -$73.0M | -$67.1M | -$32.9M |
| Net income | -$113.6M | -$69.0M | -$58.3M | -$63.1M | -$32.7M |
| Diluted EPS | -$1.83 | -$1.28 | -$1.32 | -$1.52 | — |
| Operating cash flow | -$82.2M | -$43.8M | -$50.6M | -$42.9M | -$17.0M |
| Free cash flow | -$83.3M | -$44.2M | -$52.4M | -$49.4M | -$18.5M |
| Total assets | $1.0B | $1.1B | $380.4M | $364.0M | $379.8M |
| Total liabilities | $44.7M | $38.7M | $36.1M | $43.3M | $13.5M |
| Stockholders' equity | $956.8M | $1.0B | $344.3M | $320.7M | $366.3M |
| Cash and investments | $966.6M | $1.0B | $344.0M | $327.0M | $375.0M |
| Total debt | $22.1M | $23.0M | $24.5M | $25.3M | $194,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 5, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 5, 2026 | Nov 5, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2026 | Aug 6, 2026 |
| 8-K |
Current report
Other events
|
Jun 23, 2026 | Jun 23, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 12, 2026 | Jun 11, 2026 |
All 442 Janux Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.